CD38 a biomarker and therapeutic target in non-hematopoietic tumors

CD38 a biomarker and therapeutic target in non-hematopoietic tumors

The type II transmembrane glycoprotein CD38 has recently been implicated in regulating metabolism and the pathogenesis of multiple conditions, including aging, inflammation and cancer. CD38 is overexpressed in several tumor cells and microenvironment tumoral cells, associated to migration, angiogene...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomarkers in medicine 2022-04, Vol.16 (5), p.387-400
Hauptverfasser: Barrientos-Robledo, Susana G, Cebada-Ruiz, Jorge A, Rodríguez-Alba, Juan C, Baltierra-Uribe, Shantal L, Díaz Y Orea, Maria A, Romero-Ramírez, Héctor
Format: Artikel
Sprache:eng
Schlagworte:
ADP-ribosyl Cyclase 1 - metabolism
angiogenesis
Biomarkers
CD38
cell invasion
Humans
Immunologic Factors
Immunotherapy
Neoplasms - therapy
non-hematopoietic cancer
tumor cells
Tumor Microenvironment
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The type II transmembrane glycoprotein CD38 has recently been implicated in regulating metabolism and the pathogenesis of multiple conditions, including aging, inflammation and cancer. CD38 is overexpressed in several tumor cells and microenvironment tumoral cells, associated to migration, angiogenesis, cell invasion and progression of the disease. Thus, CD38 has been used as a progression marker for different cancer types as well as in immunotherapy. This review focuses on describing the involvement of CD38 in various non-hematopoietic cancers.
ISSN:1752-0363
1752-0371
DOI:10.2217/bmm-2021-0575